Disc Medicine (IRON) is a clinical-stage biopharmaceutical company. Disc Medicine (IRON) has built deep expertise in the role of iron homeostasis in hematologic disorders. The biotech company is expanding their portfolio with these highly complementary antibody programs. CEO John Quisel weighs in on agreeing to pay $10M to Mabwell Therapeutics as a down payment.
23 Jan 2023
Morning Trade Live
14 Nov 2022
Market On Close
14 Dec 2022
The Watch List
22 Jan 2023
The Watch List
31 Jan 2023
The Watch List
09 Dec 2022